Total Raised
$107.26MInvestors Count
7Deal Terms
1Funding, Valuation & Revenue
8 Fundings
SpinalMotion's latest funding round was a Series E for $25.55M on October 3, 2013.
Date | Round | Amount | Investors | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Revenue | Sources |
---|---|---|---|---|---|---|
10/3/2013 | Series E | $25.55M | 2 | |||
11/23/2009 | Series D - II | |||||
8/18/2009 | Grant | |||||
7/21/2009 | Series D | |||||
11/15/2007 | Line of Credit |
Date | 10/3/2013 | 11/23/2009 | 8/18/2009 | 7/21/2009 | 11/15/2007 |
---|---|---|---|---|---|
Round | Series E | Series D - II | Grant | Series D | Line of Credit |
Amount | $25.55M | ||||
Investors | |||||
Valuation | |||||
Revenue | |||||
Sources | 2 |
This profile has not been claimed.
You're more than your latest funding, tell our customers your company's story.
SpinalMotion Deal Terms
1 Deal Term
SpinalMotion's deal structure is available for 1 funding round, including their Series B from March 11, 2005.
Round | Series B |
---|---|
Funding Date | |
Pre-Money Valuation | |
Post-Money Valuation | |
Amount Raised | |
Shares Authorized | |
Issuance Price | |
Dividend Rate | |
Liquidation Preferences | |
Liquidation Price | |
Participation | |
Conversion Price | |
Anti Dilution | |
General Voting | |
Board Voting | |
Par Value |
Round | Funding Date | Pre-Money Valuation | Post-Money Valuation | Amount Raised | Shares Authorized | Issuance Price | Dividend Rate | Liquidation Preferences | Liquidation Price | Participation | Conversion Price | Anti Dilution | General Voting | Board Voting | Par Value |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Series B |
SpinalMotion Investors
7 Investors
SpinalMotion has 7 investors. Three Arch Partners invested in SpinalMotion's Series C funding round.
First funding | Last Funding | Investor | Rounds | Board Seats | Type | Location |
---|---|---|---|---|---|---|
3/11/2005 | 10/3/2013 | 5 Series D, Series D - II (2009), Series B (2005), Series E (2013), Series C (2006) | Venture Capital | California | ||
Venture Capital | California | |||||
Venture Capital | California | |||||
Venture Capital | California | |||||
Corporation | Massachusetts |
First funding | 3/11/2005 | ||||
---|---|---|---|---|---|
Last Funding | 10/3/2013 | ||||
Investor | |||||
Rounds | 5 Series D, Series D - II (2009), Series B (2005), Series E (2013), Series C (2006) | ||||
Board Seats | |||||
Type | Venture Capital | Venture Capital | Venture Capital | Venture Capital | Corporation |
Location | California | California | California | California | Massachusetts |
Compare SpinalMotion to Competitors
Theken Disc, LLC founded in 2003 designs, develops and manufactures spinal arthroplasty products, such as the eDisc, a microelectronic artificial spinal disc replacement.
Spinal Restoration restores patients' lives by delivering new therapies that address unmet needs in spine health management. These therapies are minimally invasive, early interventions with clinically proven results. The company is working with a diverse, highly regarded group of clinical and scientific advisors to develop and gain regulatory approval of the Biostat System, a proprietary resorbable biologic and delivery system for the treatment of chronic disc pain, based on solid scientific and clinical evidence.
CAdisc is a unique, entirely polymeric Total Disc Replacement system for the treatment of degenerative disc disease in the lumbar and cervical spine. CAdisc-Lchar(2122) is designed to relieve pain and restore physiological quality of motion in the lumbar spine.
Gentis is a developer of minimally invasive, biomaterials-based products intended to treat the early-stage degeneration of the spine, which causes back pain. The company's first patented product, DiscCell, is a breakthrough injectable biomaterial that augments or replaces the diseased nucleus pulposus of the spinal disc.
Axial Biotech, founded in 2002 by a group of spine surgeons and geneticists, is focused on the use of genetics and the development of minimally invasive fusionless devices to advance the diagnosis and treatment of diseases and deformities of the human spine. Axial is a company to pursue DNA-based pre-symptomatic and prognostic tests for common spinal conditions which will augment current clinical and surgical practices. In its initial genetic product development initiative, Axial has made progress towards the discovery of a location in the human genome that is associated with adolescent idiopathic scoliosis. In addition, Axial's founders have developed five motion preserving, fusionless surgical devices (including such device currently being implanted in humans) that have the promise of expanding the current treatable scoliosis patient population by a factor of ten. Axial intends to use its genetic intellectual property in the development of bio-mechanical devices, and to apply its gene discovery/product development methodology to other spinal diseases. Axial (www.axialbiotech.com) is located in Salt Lake City, Utah.
Disc Dynamics has developed the DASCORTM Disc Arthroplasty System, an innovative, minimally invasive nucleus replacement treatment for patients suffering from chronic low back pain caused by Degenerative Disc Disease (DDD).
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.